Office of Medical Student Research, Oklahoma State University Center for Health Sciences, Tulsa, Oklahoma, USA.
Department of Internal Medicine, University of Oklahoma, School of Community Medicine, Tulsa, OK, United States.
Expert Rev Pharmacoecon Outcomes Res. 2022 Dec;22(8):1253-1260. doi: 10.1080/14737167.2022.2122955. Epub 2022 Sep 12.
Peptic ulcer disease (PUD) can significantly affect quality of life (QoL). These QoL outcomes are often patient-reported, and their inclusion in clinical trials supplements efficacy outcomes to provide the patients' perspective. This assese existing literature for completeness of PRO reporting across randomized controlled trials (RCTs) evaluating PUD.
This meta-epidemiological, cross-sectional study that assessed completeness of reporting among RCTs addressing management of PUD. We conducted a comprehensive literature search] to identify RCTs with a PRO as a primary or secondary outcome. These RCTs were assessed for completion of reporting according to the PRO adaptation of CONSORT checklist. RCTs were also assessed for Risk of Bias (RoB) using the Cochrane RoB 2.0 tool.
Masked, duplicate screening of 829 results = yielded a final sample of 35 RCTs. The average completeness of reporting was 32.9% according to the CONSORT-PRO adaptation. Twenty-one (of 35; 60%) of the RCTs were assessed as having 'high' risk of bias and nine (of 35; 25.71%) were assessed as having 'some concerns' for risk of bias. Bivariate regression found completeness of reporting to be positively associated with increased PRO follow-up duration, sample size, and studies with conflicts of interest.
RCTs examining the treatment and prevention of PUD with PROs as an outcome measure have deficient reporting and 'high' risk of bias according to the CONSORT-PRO and Cochrane RoB guidelines.
消化性溃疡病(PUD)可显著影响生活质量(QoL)。这些 QoL 结果通常由患者报告,将其纳入临床试验可补充疗效结果,从而提供患者视角。本研究旨在评估评估 PUD 管理的随机对照试验(RCT)中 PRO 报告的完整性。
本meta 流行病学、横断面研究评估了 RCT 中 PRO 报告的完整性。我们进行了全面的文献检索,以确定以 PRO 为主要或次要结局的 RCT。根据 CONSORT-PRO 改编版评估这些 RCT 报告的完整性。使用 Cochrane RoB 2.0 工具评估 RCT 的偏倚风险(RoB)。
对 829 项结果进行了盲法、重复筛选,最终样本为 35 项 RCT。根据 CONSORT-PRO 改编版,报告的完整性平均为 32.9%。21 项(35 项中的 60%)RCT 被评估为具有“高”偏倚风险,9 项(35 项中的 25.71%)被评估为具有偏倚风险的“一些关注”。双变量回归发现,报告的完整性与 PRO 随访时间延长、样本量增加以及存在利益冲突的研究呈正相关。
根据 CONSORT-PRO 和 Cochrane RoB 指南,评估 PRO 作为结局指标的 PUD 治疗和预防的 RCT 报告存在缺陷,且存在“高”偏倚风险。